Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
- Conditions
- Colorectal CancerEsophageal Cancer
- Registration Number
- NCT00628368
- Lead Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Brief Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This clinical trial is studying how well biological factors work in predicting response to treatment in patients with esophageal cancer or rectal cancer.
- Detailed Description
OBJECTIVES:
Primary
* Analyze various biological factors that can be used as markers to predict response to treatment and correlate with the signaling pathway of EGFR.
Secondary
* Establish a tissue bank to store information about the response to treatment and survival.
OUTLINE: Patients undergo endoscopy, 11 biopsies of tumor tissue, and 3 biopsies of healthy mucosa. Blood samples are also collected. Samples are analyzed for the expression of 4 receptors in the EGFR family, polymorphisms at intron 1 of the EGFR gene, and gene mutations in downstream signaling pathways.
After surgery, patients are followed every 3 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Role of predictive factors in the EGFR signaling pathway in response to treatment
- Secondary Outcome Measures
Name Time Method Establishment of a tissue bank
Trial Locations
- Locations (1)
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
🇫🇷Montpellier, France